drugset / Trial / NCT03449654

Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

NCT03449654

RandomizedParallel-groupDouble-blindPrevention

Summary

The objective of this study is to evaluate the mechanism behind the anti-atherogenic effects of liraglutide. In a randomized, placebo-controlled, double-blind, parallel trial we will included 100 patients with type 2 diabetes. Patients will be randomized 1:1 to an active treatment period of 26 weeks or placebo for 26 weeks. The primary endpoint is change from baseline to week 26 in vascular inflammation, assessed by Flour Deoxy Glucose (FDG)-Positron Emission Tomography/Computed Tomography (PET/CT)

Timeline

Start
2017-10-26
Primary completion
2019-08-16
Completion
2019-08-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg